203 related articles for article (PubMed ID: 11314782)
1. p53 protein expression and gene mutation in phyllodes tumors of the breast.
Gatalica Z; Finkelstein S; Lucio E; Tawfik O; Palazzo J; Hightower B; Eyzaguirre E
Pathol Res Pract; 2001; 197(3):183-7. PubMed ID: 11314782
[TBL] [Abstract][Full Text] [Related]
2. Pathologic, immunohistochemical, and molecular features of benign and malignant phyllodes tumors of the breast.
Kleer CG; Giordano TJ; Braun T; Oberman HA
Mod Pathol; 2001 Mar; 14(3):185-90. PubMed ID: 11266524
[TBL] [Abstract][Full Text] [Related]
3. Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast.
Yonemori K; Hasegawa T; Shimizu C; Shibata T; Matsumoto K; Kouno T; Ando M; Katsumata N; Fujiwara Y
Pathol Res Pract; 2006; 202(10):705-12. PubMed ID: 16889904
[TBL] [Abstract][Full Text] [Related]
4. Importance of P53, Ki-67 expression in the differential diagnosis of benign/malignant phyllodes tumors of the breast.
Kucuk U; Bayol U; Pala EE; Cumurcu S
Indian J Pathol Microbiol; 2013; 56(2):129-34. PubMed ID: 24056649
[TBL] [Abstract][Full Text] [Related]
5. Altered expression of p53 and its regulated proteins in phyllodes tumours of the breast.
Kuenen-Boumeester V; Henzen-Logmans SC; Timmermans MM; van Staveren IL; van Geel A; Peeterse HJ; Bonnema J; Berns EM
J Pathol; 1999 Oct; 189(2):169-75. PubMed ID: 10547570
[TBL] [Abstract][Full Text] [Related]
6. Tumour angiogenesis and p53 protein expression in mammary phyllodes tumors.
Tse GM; Lui PC; Scolyer RA; Putti TC; Kung FY; Law BK; Lau TS; Lee CS
Mod Pathol; 2003 Oct; 16(10):1007-13. PubMed ID: 14559983
[TBL] [Abstract][Full Text] [Related]
7. Progressive deregulation of the cell cycle with higher tumor grade in the stroma of breast phyllodes tumors.
Kuijper A; de Vos RA; Lagendijk JH; van der Wall E; van Diest PJ
Am J Clin Pathol; 2005 May; 123(5):690-8. PubMed ID: 15981808
[TBL] [Abstract][Full Text] [Related]
8. Increased p53 protein expression in malignant mammary phyllodes tumors.
Tse GM; Putti TC; Kung FY; Scolyer RA; Law BK; Lau TS; Lee CS
Mod Pathol; 2002 Jul; 15(7):734-40. PubMed ID: 12118111
[TBL] [Abstract][Full Text] [Related]
9. Patterns of p53 expression in phyllodes tumors of the breast--an immunohistochemical study.
Kim CJ; Kim WH
J Korean Med Sci; 1993 Oct; 8(5):325-8. PubMed ID: 8305139
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical and molecular markers in breast phyllodes tumors.
Korcheva VB; Levine J; Beadling C; Warrick A; Countryman G; Olson NR; Heinrich MC; Corless CL; Troxell ML
Appl Immunohistochem Mol Morphol; 2011 Mar; 19(2):119-25. PubMed ID: 21030860
[TBL] [Abstract][Full Text] [Related]
11. Genome-wide analysis for loss of heterozygosity in primary and recurrent phyllodes tumor and fibroadenoma of breast using single nucleotide polymorphism arrays.
Wang ZC; Buraimoh A; Iglehart JD; Richardson AL
Breast Cancer Res Treat; 2006 Jun; 97(3):301-9. PubMed ID: 16791486
[TBL] [Abstract][Full Text] [Related]
12. Phyllodes tumors and fibroadenoma common beginning and different ending.
Oprić S; Oprić D; Gugić D; Granić M
Coll Antropol; 2012 Mar; 36(1):235-41. PubMed ID: 22816226
[TBL] [Abstract][Full Text] [Related]
13. The Wnt pathway, epithelial-stromal interactions, and malignant progression in phyllodes tumours.
Sawyer EJ; Hanby AM; Rowan AJ; Gillett CE; Thomas RE; Poulsom R; Lakhani SR; Ellis IO; Ellis P; Tomlinson IP
J Pathol; 2002 Apr; 196(4):437-44. PubMed ID: 11920740
[TBL] [Abstract][Full Text] [Related]
14. Increased epidermal growth factor receptor (EGFR) expression in malignant mammary phyllodes tumors.
Tse GM; Lui PC; Vong JS; Lau KM; Putti TC; Karim R; Scolyer RA; Lee CS; Yu AM; Ng DC; Tse AK; Tan PH
Breast Cancer Res Treat; 2009 Apr; 114(3):441-8. PubMed ID: 18443904
[TBL] [Abstract][Full Text] [Related]
15. Expression of p53 protein and Ki-67 antigen in phyllodes tumor of the breast.
Chan YJ; Chen BF; Chang CL; Yang TL; Fan CC
J Chin Med Assoc; 2004 Jan; 67(1):3-8. PubMed ID: 15077883
[TBL] [Abstract][Full Text] [Related]
16. Phyllodes tumor of the breast: an update.
Tse GM; Niu Y; Shi HJ
Breast Cancer; 2010; 17(1):29-34. PubMed ID: 19434472
[TBL] [Abstract][Full Text] [Related]
17. Prognostic evaluation of proliferative activity and DNA content in the phyllodes tumor of the breast: immunohistochemical and flow cytometric study of 118 cases.
Niezabitowski A; Lackowska B; Rys J; Kruczak A; Kowalska T; Mitus J; Reinfuss M; Markiewicz D
Breast Cancer Res Treat; 2001 Jan; 65(1):77-85. PubMed ID: 11245343
[TBL] [Abstract][Full Text] [Related]
18. The role of p53 mutations in bilateral breast carcinoma.
Ackerman J; Baunoch DA; Gimotty P; George J; Lane MA; Dawson PJ
Mod Pathol; 1995 Apr; 8(3):244-8. PubMed ID: 7617647
[TBL] [Abstract][Full Text] [Related]
19. Evidence for a gene on 17p13.3, distal to TP53, as a target for allele loss in breast tumors without p53 mutations.
Cornelis RS; van Vliet M; Vos CB; Cleton-Jansen AM; van de Vijver MJ; Peterse JL; Khan PM; Børresen AL; Cornelisse CJ; Devilee P
Cancer Res; 1994 Aug; 54(15):4200-6. PubMed ID: 8033152
[TBL] [Abstract][Full Text] [Related]
20. Malignant phyllodes tumours show stromal overexpression of c-myc and c-kit.
Sawyer EJ; Poulsom R; Hunt FT; Jeffery R; Elia G; Ellis IO; Ellis P; Tomlinson IP; Hanby AM
J Pathol; 2003 May; 200(1):59-64. PubMed ID: 12692842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
